Fig. 8

Activation of microglia and astrocytes in transgenic mice after DHM and Sal B treatments. Alterations in cell numbers of microglia are concomitant to that of astrocytes (a and b). Representative images of the microglial marker Iba1 (a) and the astroglial marker GFAP (b) in the CS and SNpc of BAC-α-syn-GFP transgenic mice treated with DHM/Sal B or saline control (8 animals/group, male). Quantification of activated cell numbers and density of the microglial marker Iba1 (c) and the astroglial marker GFAP (d) in the CS and SNpc of BAC-α-syn-GFP transgenic mice are displayed with treatments of DHM/Sal B or saline control. IHC assessment of astrogliosis paralleled by microgliosis in transgenic mice after DHM and Sal B treatments (e-h). Representative images of Iba1+ microglia (e) and GFAP+ astroglia (g) in the CS and SNpc of BAC-α-syn-GFP transgenic mice treated with DHM and Sal B or saline. Effects of DHM and Sal B treatments in the CS and SNpc of BAC-α-syn-GFP transgenic mice compared to saline treatment are represented by quantification of optical density of the microglial marker Iba1 (f) and the astroglial marker GFAP (h) in each individual group. All values are mean + S.E.M, differences are significant at *p<0.05, **p < 0.01. Scare bar = 50 μm